Time-Resolved Spectroscopic Studies of the Photochemistry of Riboflavin, Aromatic N-Oxides and the Absolute Reactivity of Hydroxyl Radical
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
(TPZ) Prodrugs for the Management of Hypoxic Solid Tumors by Sindhuja
Evaluation of bioreductively-activated Tirapazamine (TPZ) prodrugs for the management of hypoxic solid tumors by Sindhuja Pattabhi Raman A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science in Cancer Sciences Department of Oncology University of Alberta © Sindhuja Pattabhi Raman, 2019 Abstract Solid tumors often have large areas with low levels of oxygen (termed hypoxic regions), which are associated with poor prognosis and treatment response. Tirapazamine (TPZ), a hypoxia targeting anticancer drug, started as a promising candidate to deal with this issue. However, it was withdrawn from the clinic due to severe neurotoxic side effects and poor target delivery. Hypoxic cells overexpress glucose transporters (GLUT) - a key feature during hypoxic tumor progression. Our project aims at conjugating TPZ with glucose to exploit the upregulated GLUTs for its delivery, and thereby facilitate the therapeutic management of hypoxic tumors. We hypothesized that glucose-conjugated TPZ (G6-TPZ) would be selectively recruited to these receptors, facilitating its entrapment in poorly oxygenated cells only, with minimal damage to their oxygenated counterparts. However, our results reveal that the addition of the glucose moiety to TPZ was counterproductive since G6-TPZ displayed selective hypoxic cytotoxicity only at very high concentrations of the compound. We speculate that the reduced cytotoxicity of G6-TPZ might be due to the fact that the compound was not taken up by the cells. In order to monitor the cellular uptake of TPZ, we developed a click chemistry-based approach by incorporating an azido (N3) group to our parent compound (N3-TPZ). We observed that the azido-conjugated TPZ was highly hypoxia selective and the compound successfully tracks cellular hypoxia. -
Method of Tumor Treatment
Europaisches Patentamt J European Patent Office 0 Publication number: 0 649 658 A1 Office europeen des brevets EUROPEAN PATENT APPLICATION 0 Application number: 94202693.1 mt . ci .6 :A61K 31/53 0 Date of filing: 19.09.94 0 Priority: 22.09.93 US 125609 Palo Alto, CA 94304-1850 (US) 0 Date of publication of application: 0 Inventor: Brown, Martin J. 26.04.95 Bulletin 95/17 c/o Sterling Winthrop, Inc., 90 Park Avenue 0 Designated Contracting States: New York 10016 (US) AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE 0 Representative: Le Guen, Gerard 0 Applicant: THE BOARD OF TRUSTEES OF THE CABINET LAVOIX LELAND STANFORD JUNIOR UNIVERSITY 2, place d'Estienne d'Orves 900 Welch Road, Suite 350 F-75441 Paris Cedex 09 (FR) 0 Method of tumor treatment. 0 The present invention provides methods for increasing the cytotoxicity of a chemotherapy agent towards a solid tumor, such tumor susceptible to treatment with the chemotherapy agent, comprising administering to a mammal having such a tumor, from about one half hour to about twenty-four hours prior to administering the chemotherapy agent, or from about one hour to about two hours after administering the chemotherapy agent, a cytotoxicity-enhancing amount of a compound of Formula I. The invention also provides kits for treatment of such tumors which comprise a chemotherapy agent and a cytotoxicity-enhancing amount of a 1,2,4-ben- zotriazine oxide as defined in Formula I. The present invention also provides the use of a compound of Formula I capable of exerting a cytotoxic- enhancing effect on a cancer tumor for the manufacture of a medicament, for the therapeutic administration to a mammal having such a tumour from about one half hour to about twenty-four hours prior to treatment of said tumor with a chemotherapy agent. -
Toxic Fungi of Western North America
Toxic Fungi of Western North America by Thomas J. Duffy, MD Published by MykoWeb (www.mykoweb.com) March, 2008 (Web) August, 2008 (PDF) 2 Toxic Fungi of Western North America Copyright © 2008 by Thomas J. Duffy & Michael G. Wood Toxic Fungi of Western North America 3 Contents Introductory Material ........................................................................................... 7 Dedication ............................................................................................................... 7 Preface .................................................................................................................... 7 Acknowledgements ................................................................................................. 7 An Introduction to Mushrooms & Mushroom Poisoning .............................. 9 Introduction and collection of specimens .............................................................. 9 General overview of mushroom poisonings ......................................................... 10 Ecology and general anatomy of fungi ................................................................ 11 Description and habitat of Amanita phalloides and Amanita ocreata .............. 14 History of Amanita ocreata and Amanita phalloides in the West ..................... 18 The classical history of Amanita phalloides and related species ....................... 20 Mushroom poisoning case registry ...................................................................... 21 “Look-Alike” mushrooms ..................................................................................... -
Date: 1/9/2017 Question: Botulism Is an Uncommon Disorder Caused By
6728 Old McLean Village Drive, McLean, VA 22101 Tel: 571.488.6000 Fax: 703.556.8729 www.clintox.org Date: 1/9/2017 Question: Botulism is an uncommon disorder caused by toxins produced by Clostridium botulinum. Seven subtypes of botulinum toxin exist (subtypes A, B, C, D, E, F and G). Which subtypes have been noted to cause human disease and which ones have been reported to cause infant botulism specifically in the United States? Answer: According to the cited reference “Only subtypes A, B, E and F cause disease in humans, and almost all cases of infant botulism in the United States are caused by subtypes A and B. Botulinum-like toxins E and F are produced by Clostridium baratii and Clostridium butyricum and are only rarely implicated in infant botulism” (Rosow RK and Strober JB. Infant botulism: Review and clinical update. 2015 Pediatr Neurol 52: 487-492) Date: 1/10/2017 Question: A variety of clinical forms of botulism have been recognized. These include wound botulism, food borne botulism, and infant botulism. What is the most common form of botulism reported in the United States? Answer: According to the cited reference, “In the United States, infant botulism is by far the most common form [of botulism], constituting approximately 65% of reported botulism cases per year. Outside the United States, infant botulism is less common.” (Rosow RK and Strober JB. Infant botulism: Review and clinical update. 2015 Pediatr Neurol 52: 487-492) Date: 1/11/2017 Question: Which foodborne pathogen accounts for approximately 20 percent of bacterial meningitis in individuals older than 60 years of age and has been associated with unpasteurized milk and soft cheese ingestion? Answer: According to the cited reference, “Listeria monocytogenes, a gram-positive rod, is a foodborne pathogen with a tropism for the central nervous system. -
Theranostics Self-Accelerating H2O2-Responsive Plasmonic
Theranostics 2020, Vol. 10, Issue 19 8691 Ivyspring International Publisher Theranostics 2020; 10(19): 8691-8704. doi: 10.7150/thno.45392 Research Paper Self-accelerating H2O2-responsive Plasmonic Nanovesicles for Synergistic Chemo/starving therapy of Tumors Yao Tang1, Yuejia Ji1, Chenglin Yi2, Di Cheng1, Bin Wang1, Yun Fu1, Yufang Xu1, Xuhong Qian1, Yahya E. Choonara3, Viness Pillay3, Weiping Zhu1, Yunen Liu4 and Zhihong Nie2 1. State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of Chemical Biology, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China. 2. State Key Laboratory of Molecular Engineering of Polymers, Department of Macromolecular Science, Fudan University, Shanghai 200438, China. 3. Department of Pharmacy and Pharmacology, University of the Witwatersrand, Parktown 2193 Johannesburg, South Africa. 4. Department of Emergency Medicine, the General Hospital of Northern Theater Command, Laboratory of Rescue Center of Severe Trauma PLA, Shenyang l10016, China. Corresponding author: E-mails: [email protected] (Z. Nie); [email protected] (Y. Liu); [email protected] (W. Zhu). © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2020.02.27; Accepted: 2020.06.17; Published: 2020.07.09 Abstract Rationale: Nanoscale vehicles responsive to abnormal variation in tumor environment are promising for use in targeted delivery of therapeutic drugs specifically to tumor sites. Herein, we report the design and fabrication of self-accelerating H2O2-responsive plasmonic gold nanovesicles (GVs) encapsulated with tirapazamine (TPZ) and glucose oxidase (GOx) for synergistic chemo/starving therapy of cancers. -
Improved Tissue-Based Analytical Test Methods for Orellanine, a Biomarker of Cortinarius Mushroom Intoxication
toxins Article Improved Tissue-Based Analytical Test Methods for Orellanine, a Biomarker of Cortinarius Mushroom Intoxication Poojya Anantharam 1, Dahai Shao 1, Paula M. Imerman 1, Eric Burrough 1, Dwayne Schrunk 1, Tsevelmaa Sedkhuu 2, Shusheng Tang 3 and Wilson Rumbeiha 1,* 1 Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA; [email protected] (P.A.); [email protected] (D.S.); [email protected] (P.M.I.); [email protected] (E.B.); [email protected] (D.S.) 2 State Central Veterinary Laboratory, 8200 Zaisan, Khan-Uul District, Ulaanbaatar 017024, Mongolia; [email protected] 3 College of Veterinary Medicine, China Agricultural University, No. 2 Yuanmingyuan West Road, Haidian District, Beijing 100193, China; [email protected] * Correspondence: [email protected]; Tel.: +1-515-294-0630 Academic Editor: Jack Ho Wong Received: 4 March 2016; Accepted: 11 May 2016; Published: 21 May 2016 Abstract: Orellanine (OR) toxin is produced by mushrooms of the genus Cortinarius which grow in North America and in Europe. OR poisoning is characterized by severe oliguric acute renal failure, with a mortality rate of 10%–30%. Diagnosis of OR poisoning currently hinges on a history of ingestion of Cortinarius mushrooms and histopathology of renal biopsies. A key step in the diagnostic approach is analysis of tissues for OR. Currently, tissue-based analytical methods for OR are nonspecific and lack sensitivity. The objectives of this study were: (1) to develop definitive HPLC and LC-MS/MS tissue-based analytical methods for OR; and (2) to investigate toxicological effects of OR in mice. -
(12) Patent Application Publication (10) Pub. No.: US 2006/0216288 A1 Chang (43) Pub
US 20060216288A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0216288 A1 Chang (43) Pub. Date: Sep. 28, 2006 (54) COMBINATIONS FOR THE TREATMENT OF Publication Classification CANCER (51) Int. Cl. (75) Inventor: David Chang, Calabasas, CA (US) A 6LX 39/395 (2006.01) A6II 3/55 (2006.01) Correspondence Address: A6II 3 L/4545 (2006.01) SESS is 2-C A61K 31/4439 (2006.01) ONE AMGEN CENTERY DRIVE A6II 3/44 (2006.O1 ) THOUSAND OAKS, CA 91320-1799 (US) (52) U.S. Cl. ................... 424/143.1: 514/352: 514/210.2: (73) Assignee: Amgen Inc., Thousand Oaks, CA 514/318: 514/340; 514/217.04 (21) Appl. No.: 11/386,271 (22) Filed: Mar. 21, 2006 (57) ABSTRACT Related U.S. Application Data This invention is in the field of pharmaceutical agents and (60) Provisional application No. 60/664,381, filed on Mar. specifically relates to compounds, compositions, uses and 22, 2005. methods for treating cancer. Patent Application Publication Sep. 28, 2006 Sheet 1 of 5 US 2006/0216288A1 Figure 1 -- Vehicle X Compound B, 10 mpk 1800 -- Antibody A, 20 ug 1600 Compound B, 10 mpk+ 1400 Antibody A, 20 ug 1200 1000 800 600 p = 0.0003 1/10 1110 1/10 p < 0.0001 v v v v v v V 174. 22 27 32 37 42 47 Time (days) V Antibody A injection Patent Application Publication Sep. 28, 2006 Sheet 2 of 5 US 2006/0216288A1 Figure 2 -- Vehicle 1800 X Compound B, 75 mpk 1600 th- Antibody A, 500 u 1400 dy 9 1200 Compound B, 75 mpk+ Antibody A, 500 ug 1000 800 600 V Antibodyy A, ipp injectionin 400 200 p < 0.0001 st 0.9515 V. -
Structure Elucidation of a New Toxin from the Mushroom Cortinarius Rubellus Using Gas Chromatography-Mass Spectrometry (GC-MS)
International Journal of Analytical Mass Spectrometry and Chromatography, 2013, 1, 109-118 Published Online December 2013 (http://www.scirp.org/journal/ijamsc) http://dx.doi.org/10.4236/ijamsc.2013.12014 Structure Elucidation of a New Toxin from the Mushroom Cortinarius rubellus Using Gas Chromatography-Mass Spectrometry (GC-MS) Ilia Brondz1,2 1Department of Biosciences, University of Oslo, Oslo, Norway 2R & D Department of Jupiter Ltd., Ski, Norway Email: [email protected], [email protected] Received October 28, 2013; revised November 24, 2013; accepted December 27, 2013 Copyright © 2013 Ilia Brondz. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Cortinarius orellanus (Fries) and C. rubellus (Cooke), which were formerly also known as C. speciosissimus, are poi- sonous mushrooms containing the toxin orellanine and several degradation products of orellanine, including orelline and orellinine. Mass intoxication by poisonous mushrooms was observed in Poland in 1952-1957 [1]. In 1957, the cause of these outbreaks was described by Grzymala as poisoning by a member of the Cortinarius family. The toxin orellanine was first isolated from C. orellanus by Grzymala in 1962; the chemical structure of orellanine was later de- termined to be 3,3,4,4-tetrahydroxy-2,2-bipyridine-N,N-dioxide. Poisoning with C. orellanus and C. rubellus has a very specific character. The first symptoms of intoxication usually do not appear until 2 - 3 days after ingestion, but in some cases intoxication appears after three weeks. -
Poisoning Associated with the Use of Mushrooms a Review of the Global
Food and Chemical Toxicology 128 (2019) 267–279 Contents lists available at ScienceDirect Food and Chemical Toxicology journal homepage: www.elsevier.com/locate/foodchemtox Review Poisoning associated with the use of mushrooms: A review of the global T pattern and main characteristics ∗ Sergey Govorushkoa,b, , Ramin Rezaeec,d,e,f, Josef Dumanovg, Aristidis Tsatsakish a Pacific Geographical Institute, 7 Radio St., Vladivostok, 690041, Russia b Far Eastern Federal University, 8 Sukhanova St, Vladivostok, 690950, Russia c Clinical Research Unit, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran d Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran e Aristotle University of Thessaloniki, Department of Chemical Engineering, Environmental Engineering Laboratory, University Campus, Thessaloniki, 54124, Greece f HERACLES Research Center on the Exposome and Health, Center for Interdisciplinary Research and Innovation, Balkan Center, Bldg. B, 10th km Thessaloniki-Thermi Road, 57001, Greece g Mycological Institute USA EU, SubClinical Research Group, Sparta, NJ, 07871, United States h Laboratory of Toxicology, University of Crete, Voutes, Heraklion, Crete, 71003, Greece ARTICLE INFO ABSTRACT Keywords: Worldwide, special attention has been paid to wild mushrooms-induced poisoning. This review article provides a Mushroom consumption report on the global pattern and characteristics of mushroom poisoning and identifies the magnitude of mortality Globe induced by mushroom poisoning. In this work, reasons underlying mushrooms-induced poisoning, and con- Mortality tamination of edible mushrooms by heavy metals and radionuclides, are provided. Moreover, a perspective of Mushrooms factors affecting the clinical signs of such toxicities (e.g. consumed species, the amount of eaten mushroom, Poisoning season, geographical location, method of preparation, and individual response to toxins) as well as mushroom Toxins toxins and approaches suggested to protect humans against mushroom poisoning, are presented. -
Curriculum Vitae for Prof Søren M
CURRICULUM VITÆ FOR PROFESSOR SØREN M. BENTZEN Full Name: Søren Møller Bentzen Title: Professor, Director of the Division of Biostatistics and Bioinformatics, Department of Epidemiology and Public Health, Director of the University of Maryland Greenebaum Comprehensive Cancer Center Biostatistics Shared Service, Director of the Biostatistics Core of the Institute of Clinical and Translational Research, and Director of Translational Research, Maryland Proton Therapy Alliance, University of Maryland School of Medicine Academic Credentials : M.Sc., Ph.D., D.M.Sc., F.A.S.T.R.O. Affiliations: Professor, tenured, Department of Epidemiology and Public Health, primary faculty appointment, University of Maryland School of Medicine, Baltimore, MD, USA Professor of Radiation Oncology, secondary faculty appointment, University of Maryland School of Medicine, Baltimore, MD, USA Director, Division of Biostatistics and Bioinformatics, Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, USA Director, University of Maryland Greenebaum Comprehensive Cancer Center Biostatistics Shared Service, University of Baltimore School of Medicine, Baltimore, MD, USA Director, Biostatistics Core, Institute for Clinical and Translational Research, University of Maryland Baltimore, Baltimore, MD, USA Director of Translational Research, Maryland Proton Alliance, University of Baltimore School of Medicine, Baltimore, MD, USA Member, University of Maryland Greenebaum Comprehensive Cancer Center, Experimental Therapeutics -
(12) Patent Application Publication (10) Pub. No.: US 2010/0152243 A1 Haraldsson Et Al
US 20100152243A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0152243 A1 Haraldsson et al. (43) Pub. Date: Jun. 17, 2010 (54) TREATMENT OF RENAL CELL Publication Classification CARCINOMA (51) Int. Cl. (76) Inventors: Börje Haraldsson, Landvetter A61K 3/444 (2006.01) (SE); Ulf Nilsson, Gothenburg (SE): A6IP35/00 (2006.01) Lisa Buvall, Lerum (SE); Jenny Nyström, Gothenburg (SE) (52) U.S. Cl. ........................................................ S14/334 Correspondence Address: LYNN E BARBER PO BOX 16528 FORTWORTH, TX 76162 (US) (57) ABSTRACT Methods are provided of treating renal cancer by administra (21) Appl. No.: 12/586,849 tion of certain 3.3',4,4-tetrahydroxy-2,2'-bipyridine-N,N'-di (22) Filed: Sep. 29, 2009 oxide compounds, especially 3,3',4,4-tetrahydroxy-2,2'-bi pyridine-N,N'-dioxide (Orellanine), using particular Related U.S. Application Data administration protocols and dosing regimens, as well as (60) Provisional application No. 61/195.312, filed on Oct. pharmaceutical compositions Suitable for use in the treatment 6, 2008. methods that are provided. Patent Application Publication Jun. 17, 2010 Sheet 1 of 8 US 2010/0152243 A1 to attoo/pehea. Ace? Patent Application Publication Jun. 17, 2010 Sheet 2 of 8 US 2010/0152243 A1 } uoqueqnou?auquerrauojo»?aawaauouængesuedo-99/ Patent Application Publication Jun. 17, 2010 Sheet 4 of 8 US 2010/0152243 A1 w‘914 josºsopp3?eadauzJe??eA?I?qe?ASOMOO (£=u)auquelleloluu/ºrioz enxa?sop3|3u?Suzzasopeu?kaqvzesop Patent Application Publication Jun. 17, 2010 Sheet 5 of 8 US 2010/0152243 A1 p2 Rb (Ser795) Rb (Ser807/8 Coo Figs tre is Patent Application Publication Jun. -
The Role of Free Radicals in the Effectiveness of Anti-Cancer Chemotherapy in Hypoxic Ovarian Cells and Tumours Clifford Fong
The role of free radicals in the effectiveness of anti-cancer chemotherapy in hypoxic ovarian cells and tumours Clifford Fong To cite this version: Clifford Fong. The role of free radicals in the effectiveness of anti-cancer chemotherapy in hypoxic ovar- ian cells and tumours. [Research Report] Eigenenergy, Adelaide, Australia. 2017. hal-01659879v2 HAL Id: hal-01659879 https://hal.archives-ouvertes.fr/hal-01659879v2 Submitted on 18 Feb 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. The role of free radicals in the effectiveness of anti-cancer chemotherapy in hypoxic ovarian cells and tumours Clifford W. Fong Eigenenergy, Adelaide, South Australia, Australia. Email: [email protected] Keywords: ovarian cancer; cytotoxicity; hypoxia; anoxia; normoxia; free radicals; electron affinity; Abstract It has been shown that strong linear relationships exist between the hypoxic and anoxic cytotoxicity ratios for the A2780 human ovarian cancer cell lines and the adiabatic electron affinity for 17 currently clinically used or subclinical anti-cancer drugs. A similar linear relationship is also found for the cytotoxicity ratios under normoxia, but the effect is the opposite to those found for anoxia and hypoxia.